Fresenius Medical Care Renal Therapies Group Announces Chief Medical Officer to Retire
April 08 2014 - 6:02AM
Business Wire
Incoming CMO of company’s products business to
assume position as of July 1, 2014
Fresenius Medical Care Renal Therapies Group (RTG) , the
continent’s leading provider of kidney care products, announced
today that Dr. Jose A. Diaz-Buxo, Chief Medical Officer and Senior
Vice President, has decided to retire as of May 31. Dr. Robert
Kossmann will assume this position beginning July 1.
Dr. Diaz-Buxo joined Fresenius Medical Care North America
(FMCNA) in 1996 as president of the company’s Peritoneal Dialysis
Services and was named RTG’s Chief Medical Officer in 2004. During
his tenure he played a critical role in leading the development of
devices and drugs designed to improve the quality of life and
longevity of patients on dialysis. This included his invention of
Continuous Cycling Peritoneal Dialysis (CCPD) and PD Plus Therapy,
and his leadership and contributions to peritoneal kinetics. Dr.
Diaz-Buxo has published more than 300 peer-reviewed publications on
these and other important areas of dialysis.
RTG has named Dr. Robert Kossmann as its incoming Chief Medical
Officer. He will assume this position following Dr. Diaz-Buxo’s
retirement. Dr. Kossmann is a nephrologist in Santa Fe, N.M., a
member of the volunteer clinical faculty at the University of New
Mexico’s Department of Medicine, and has served extensively in the
renal care field. His roles have included; President of the Renal
Physicians Association, nephrology advisor to the American Medical
Association’s Relative Value Scale Update Committee, founding
member of the Nephrology Coverage Advocacy Program, and founder of
the New Mexico Renal Disease Collaborative Group.
“Jose Diaz-Buxo has served as a trusted adviser and mentor to so
many people at FMCNA and RTG. He will be missed and we wish him
well as he embarks on a new chapter in his life,” said Mark
Costanzo, President, Renal Therapies Group. “We are excited about
the continuity of excellence that Rob Kossmann will bring to our
Chief Medical Officer role. Rob has significant clinical experience
and industry knowledge that will serve RTG well into the
future.”
In his new role, Dr. Kossmann will have the opportunity to work
closely with Dr. Frank Maddux, Chief Medical Officer and Executive
Vice President for Clinical and Scientific Affairs for FMCNA, as
well as medical leaders of RTG's other renal care customers, in
their commitment to continually improve therapy for patients.
About Fresenius Medical Care Renal
Therapies Group
Fresenius Medical Care Renal Therapies Group (RTG) is North
America’s top producer of dialysis equipment, dialyzers and related
disposable products and a major supplier of renal pharmaceuticals.
Renal Therapies Group is a division of Fresenius Medical Care North
America, the continent’s leading provider of renal care. For more
information about Renal Therapies Group and Fresenius Medical Care
North America, visit www.fmcna.com.
Fresenius Medical CareJon Stone, 781-699-9704781-392-4680
(cell)Jonathan.d.stone@fmc-na.com
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024